ARTICLE
9 December 2013

Finnegan eBook Summarizes Various AIA Considerations And U.S. Patent Trends In Chemical And Pharmaceutical Industries

FH
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Contributor

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is a law firm dedicated to advancing ideas, discoveries, and innovations that drive businesses around the world. From offices in the United States, Europe, and Asia, Finnegan works with leading innovators to protect, advocate, and leverage their most important intellectual property (IP) assets.
On December 2, 2013, Finnegan launched The Chemical and Pharmaceutical Innovation Report 2013.
United States Intellectual Property

On December 2, 2013, Finnegan launched The Chemical and Pharmaceutical Innovation Report 2013. The Report is a complementary eBook for patent practitioners, entrepreneurs, business executives, venture capitalists, and inventors that benchmarks the patent activities in the chemical and pharmaceutical industries from 2006 to 2012.

The Report includes concise summaries of the changes under the America Invents Act ("AIA"). The AIA sections summarized include: best mode, derivation proceedings, first-inventor-to-file, inter partes review, post grant review, pre-issuance submissions, and supplemental examination. These summaries identify considerations for developing and optimizing patent strategies and describe the various proceedings that may be utilized in lieu of or in addition to litigation.

The Report 2013 also details chemical and pharmaceutical patenting and application publication trends, district court litigation trends, appellate litigation trends, and categorizes Federal Circuit decisions from 2006 to 2012.

Download a complimentary copy of The Report 2013 eBook here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More